U01 DK061010/DK/NIDDK NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2011	3
2012	5
2013	13
2014	13
2015	18
2016	19
2017	19
2018	25
2019	24
2020	23
2021	11
2022	9
2023	7
2024	7
2025	6

1

Activated polyreactive B cells are clonally expanded in autoantibody positive and patients with recent-onset type 1 diabetes.

Nicholas CA, Tensun FA, Evans SA, Toole KP, Prendergast JE, Broncucia H, Hesselberth JR, Gottlieb PA, Wells KL, Smith MJ. Nicholas CA, et al. Cell Rep. 2025 Apr 22;44(4):115425. doi: 10.1016/j.celrep.2025.115425. Epub 2025 Mar 19. Cell Rep. 2025. PMID: 40117290 Free PMC article.

2

IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes.

Sims EK, Cuthbertson D, Ferrat LA, Bosi E, Evans-Molina C, DiMeglio LA, Nathan BM, Ismail HM, Jacobsen LM, Redondo MJ, Oram RA, Sosenko JM. Sims EK, et al. Diabetologia. 2025 May;68(5):993-1004. doi: 10.1007/s00125-025-06382-x. Epub 2025 Feb 28. Diabetologia. 2025. PMID: 40016443 Free PMC article.

3

A type 1 diabetes prediction model has utility across multiple screening settings with recalibration.

Templeman EL, Ferrat LA, Parikh HM, You L, Triolo TM, Steck AK, Hagopian WA, Vehik K, Onengut-Gumuscu S, Gottlieb PA, Rich SS, Krischer JP, Redondo MJ, Oram RA; Type 1 diabetes TrialNet Study Group. Templeman EL, et al. Res Sq [Preprint]. 2025 Feb 6:rs.3.rs-5773430. doi: 10.21203/rs.3.rs-5773430/v1. Res Sq. 2025. PMID: 39975907 Free PMC article. Preprint.

4

A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts.

Sosenko JM, Cuthbertson D, Jacobsen LM, Redondo MJ, Sims EK, Ismail HM, Herold KC, Skyler JS, Nathan BM; DPT-1 and TrialNet Study Groups. Sosenko JM, et al. Diabetes Technol Ther. 2025 Mar;27(3):179-186. doi: 10.1089/dia.2024.0422. Epub 2025 Jan 6. Diabetes Technol Ther. 2025. PMID: 39757867

5

Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab.

Galderisi A, Sims EK, Evans-Molina C, Petrelli A, Cuthbertson D, Nathan BM, Ismail HM, Herold KC, Moran A. Galderisi A, et al. Diabetologia. 2025 Mar;68(3):646-661. doi: 10.1007/s00125-024-06323-0. Epub 2024 Nov 19. Diabetologia. 2025. PMID: 39560746 Free PMC article. Clinical Trial.

6

Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop.

Greenbaum CJ, Nepom GT, Wood-Heickman LK, Wherrett DK, DiMeglio LA, Herold KC, Krischer JP. Greenbaum CJ, et al. Diabetes. 2024 Nov 1;73(11):1780-1790. doi: 10.2337/dbi24-0020. Diabetes. 2024. PMID: 39167668 Review.

7

Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes.

Lledó-Delgado A, Preston-Hurlburt P, Currie S, Clark P, Linsley PS, Long SA, Liu C, Koroleva G, Martins AJ, Tsang JS, Herold KC. Lledó-Delgado A, et al. J Clin Invest. 2024 Aug 13;134(18):e177492. doi: 10.1172/JCI177492. J Clin Invest. 2024. PMID: 39137044 Free PMC article. Clinical Trial.

8

Identification of type 1 diabetes risk phenotypes using an outcome-guided clustering analysis.

You L, Ferrat LA, Oram RA, Parikh HM, Steck AK, Krischer J, Redondo MJ; Type 1 Diabetes TrialNet Study Group. You L, et al. Diabetologia. 2024 Nov;67(11):2507-2517. doi: 10.1007/s00125-024-06246-w. Epub 2024 Aug 6. Diabetologia. 2024. PMID: 39103721

9

Genetic Associations With C-peptide Levels Before Type 1 Diabetes Diagnosis in At-risk Relatives.

Triolo TM, Parikh HM, Tosur M, Ferrat LA, You L, Gottlieb PA, Oram RA, Onengut-Gumuscu S, Krischer JP, Rich SS, Steck AK, Redondo MJ. Triolo TM, et al. J Clin Endocrinol Metab. 2025 Mar 17;110(4):e1046-e1050. doi: 10.1210/clinem/dgae349. J Clin Endocrinol Metab. 2025. PMID: 38767115 Free PMC article.

10

Beyond Stages: Predicting Individual Time Dependent Risk for Type 1 Diabetes.

Pribitzer S, O'Rourke C, Ylescupidez A, Smithmyer M, Bender C, Speake C, Lord S, Greenbaum CJ. Pribitzer S, et al. J Clin Endocrinol Metab. 2024 Nov 18;109(12):3211-3219. doi: 10.1210/clinem/dgae292. J Clin Endocrinol Metab. 2024. PMID: 38712386 Free PMC article.

11

Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials.

Jacobsen LM, Cuthbertson D, Bundy BN, Atkinson MA, Moore W, Haller MJ, Russell WE, Gitelman SE, Herold KC, Redondo MJ, Sims EK, Wherrett DK, Moran A, Pugliese A, Gottlieb PA, Sosenko JM, Ismail HM; Type 1 Diabetes TrialNet Study Group. Jacobsen LM, et al. Diabetes Care. 2024 Jun 1;47(6):1048-1055. doi: 10.2337/dc24-0171. Diabetes Care. 2024. PMID: 38621411

12

Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals.

Sims EK, Cuthbertson D, Jacobsen L, Ismail HM, Nathan BM, Herold KC, Redondo MJ, Sosenko J. Sims EK, et al. J Clin Endocrinol Metab. 2024 Jul 12;109(8):2116-2123. doi: 10.1210/clinem/dgae048. J Clin Endocrinol Metab. 2024. PMID: 38267821 Free PMC article. Clinical Trial.

13

A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes.

Ylescupidez A, Bahnson HT, O'Rourke C, Lord S, Speake C, Greenbaum CJ. Ylescupidez A, et al. Nat Commun. 2023 Nov 8;14(1):7214. doi: 10.1038/s41467-023-42581-z. Nat Commun. 2023. PMID: 37940642 Free PMC article.

14

Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013.

Russell WE, Moore DJ, Herold KC. Russell WE, et al. Diabetes Care. 2023 Nov 1;46(11):e210-e211. doi: 10.2337/dci23-0050. Diabetes Care. 2023. PMID: 37890101 Free PMC article. No abstract available.

15

Type 1 Diabetes Risk Phenotypes Using Cluster Analysis.

You L, Ferrat LA, Oram RA, Parikh HM, Steck AK, Krischer J, Redondo MJ; Type 1 Diabetes TrialNet Study Group. You L, et al. medRxiv [Preprint]. 2023 Oct 12:2023.10.10.23296375. doi: 10.1101/2023.10.10.23296375. medRxiv. 2023. Update in: Diabetologia. 2024 Nov;67(11):2507-2517. doi: 10.1007/s00125-024-06246-w. PMID: 37873281 Free PMC article. Updated. Preprint.

16

High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment.

Sims EK, Geyer SM, Long SA, Herold KC. Sims EK, et al. Diabetologia. 2023 Dec;66(12):2283-2291. doi: 10.1007/s00125-023-06003-5. Epub 2023 Sep 4. Diabetologia. 2023. PMID: 37667106 Free PMC article.

17

Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet Autoantibodies.

Sosenko JM, Cuthbertson D, Sims EK, Ismail HM, Nathan BM, Jacobsen LM, Atkinson MA, Evans-Molina C, Herold KC, Skyler JS, Redondo MJ; TrialNet Study Group. Sosenko JM, et al. Diabetes Care. 2023 May 1;46(5):1098-1105. doi: 10.2337/dc22-2236. Diabetes Care. 2023. PMID: 37000695 Free PMC article.

18

Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.

Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC; Type 1 Diabetes TrialNet Study Group. Russell WE, et al. Diabetes Care. 2023 May 1;46(5):1005-1013. doi: 10.2337/dc22-2200. Diabetes Care. 2023. PMID: 36920087 Free PMC article. Clinical Trial.

19

Persistence of β-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at Screening.

Sims EK, Cuthbertson D, Felton JL, Ismail HM, Nathan BM, Jacobsen LM, Paprocki E, Pugliese A, Palmer J, Atkinson M, Evans-Molina C, Skyler JS, Redondo MJ, Herold KC, Sosenko JM. Sims EK, et al. Diabetes Care. 2022 Dec 1;45(12):2982-2990. doi: 10.2337/dc22-1362. Diabetes Care. 2022. PMID: 36326757 Free PMC article.

20

Risk Modeling to Reduce Monitoring of an Autoantibody-Positive Population to Prevent DKA at Type 1 Diabetes Diagnosis.

O'Rourke C, Ylescupidez A, Bahnson HT, Bender C, Speake C, Lord S, Greenbaum CJ. O'Rourke C, et al. J Clin Endocrinol Metab. 2023 Feb 15;108(3):688-696. doi: 10.1210/clinem/dgac594. J Clin Endocrinol Metab. 2023. PMID: 36227635 Free PMC article.

21

Decreased occurrence of ketoacidosis and preservation of beta cell function in relatives screened and monitored for type 1 diabetes in Australia and New Zealand.

Wentworth JM, Oakey H, Craig ME, Couper JJ, Cameron FJ, Davis EA, Lafferty AR, Harris M, Wheeler BJ, Jefferies C, Colman PG, Harrison LC. Wentworth JM, et al. Pediatr Diabetes. 2022 Dec;23(8):1594-1601. doi: 10.1111/pedi.13422. Epub 2022 Oct 7. Pediatr Diabetes. 2022. PMID: 36175392 Free PMC article.

22

The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk.

Ismail HM, Cuthbertson D, Gitelman SE, Skyler JS, Steck AK, Rodriguez H, Atkinson M, Nathan BM, Redondo MJ, Herold KC, Evans-Molina C, DiMeglio LA, Sosenko J; DPT-1 and TrialNet Study Groups. Ismail HM, et al. Diabetes Care. 2022 Oct 1;45(10):2264-2270. doi: 10.2337/dc22-0167. Diabetes Care. 2022. PMID: 35998266 Free PMC article.

23

Index60 Is Superior to HbA1c for Identifying Individuals at High Risk for Type 1 Diabetes.

Jacobsen LM, Bundy BN, Ismail HM, Clements M, Warnock M, Geyer S, Schatz DA, Sosenko JM. Jacobsen LM, et al. J Clin Endocrinol Metab. 2022 Sep 28;107(10):2784-2792. doi: 10.1210/clinem/dgac440. J Clin Endocrinol Metab. 2022. PMID: 35880956 Free PMC article.

24

Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes.

Baidal DA, Warnock M, Xu P, Geyer S, Marks JB, Moran A, Sosenko J, Evans-Molina C. Baidal DA, et al. J Clin Endocrinol Metab. 2022 Jul 14;107(8):e3273-e3280. doi: 10.1210/clinem/dgac285. J Clin Endocrinol Metab. 2022. PMID: 35524749 Free PMC article.

25

Characterising the age-dependent effects of risk factors on type 1 diabetes progression.

So M, O'Rourke C, Ylescupidez A, Bahnson HT, Steck AK, Wentworth JM, Bruggeman BS, Lord S, Greenbaum CJ, Speake C. So M, et al. Diabetologia. 2022 Apr;65(4):684-694. doi: 10.1007/s00125-021-05647-5. Epub 2022 Jan 18. Diabetologia. 2022. PMID: 35041021 Free PMC article.

26

Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes.

Nathan BM, Redondo MJ, Ismail H, Jacobsen L, Sims EK, Palmer J, Skyler J, Bocchino L, Geyer S, Sosenko JM. Nathan BM, et al. Diabetes Care. 2022 Feb 1;45(2):311-318. doi: 10.2337/dc21-0944. Diabetes Care. 2022. PMID: 34853027 Free PMC article.

27

Association of High-Affinity Autoantibodies With Type 1 Diabetes High-Risk HLA Haplotypes.

Triolo TM, Pyle L, Broncucia H, Armstrong T, Yu L, Gottlieb PA, Steck AK. Triolo TM, et al. J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1510-e1517. doi: 10.1210/clinem/dgab853. J Clin Endocrinol Metab. 2022. PMID: 34850014 Free PMC article.

28

HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants.

Felton JL, Cuthbertson D, Warnock M, Lohano K, Meah F, Wentworth JM, Sosenko J, Evans-Molina C; Type 1 Diabetes TrialNet Study Group. Felton JL, et al. Diabetologia. 2022 Jan;65(1):88-100. doi: 10.1007/s00125-021-05573-6. Epub 2021 Oct 12. Diabetologia. 2022. PMID: 34642772 Free PMC article.

29

Reduced Follicular Regulatory T Cells in Spleen and Pancreatic Lymph Nodes of Patients With Type 1 Diabetes.

Vecchione A, Jofra T, Gerosa J, Shankwitz K, Di Fonte R, Galvani G, Ippolito E, Cicalese MP, Schultz AR, Seay HR, Favellato M, Milardi G, Stabilini A, Ragogna F, Grogan P, Bianconi E, Laurenzi A, Caretto A, Nano R, Melzi R, Danzl N, Bosi E, Piemonti L, Aiuti A, Brusko T, Petrovas C, Battaglia M, Fousteri G. Vecchione A, et al. Diabetes. 2021 Dec;70(12):2892-2902. doi: 10.2337/db21-0091. Epub 2021 Oct 7. Diabetes. 2021. PMID: 34620616 Free PMC article.

30

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes.

Sims EK, Cuthbertson D, Herold KC, Sosenko JM. Sims EK, et al. Diabetes. 2021 Dec;70(12):2922-2931. doi: 10.2337/db21-0519. Epub 2021 Sep 22. Diabetes. 2021. PMID: 34551936 Free PMC article. Clinical Trial.

31

Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts.

Voss MG, Cuthbertson DD, Cleves MM, Xu P, Evans-Molina C, Palmer JP, Redondo MJ, Steck AK, Lundgren M, Larsson H, Moore WV, Atkinson MA, Sosenko JM, Ismail HM; DPT-1 and TrialNet Study Groups. Voss MG, et al. Diabetes Care. 2021 Oct;44(10):2329-2336. doi: 10.2337/dc21-0226. Epub 2021 Aug 6. Diabetes Care. 2021. PMID: 34362815 Free PMC article. Clinical Trial.

32

Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.

Bediaga NG, Li-Wai-Suen CSN, Haller MJ, Gitelman SE, Evans-Molina C, Gottlieb PA, Hippich M, Ziegler AG, Lernmark A, DiMeglio LA, Wherrett DK, Colman PG, Harrison LC, Wentworth JM. Bediaga NG, et al. Diabetologia. 2021 Nov;64(11):2432-2444. doi: 10.1007/s00125-021-05523-2. Epub 2021 Aug 2. Diabetologia. 2021. PMID: 34338806 Free PMC article.

33

TCF7L2 Genetic Variants Do Not Influence Insulin Sensitivity or Secretion Indices in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes.

Redondo MJ, Warnock MV, Libman IM, Bocchino LE, Cuthbertson D, Geyer S, Pugliese A, Steck AK, Evans-Molina C, Becker D, Sosenko JM, Bacha F; Type 1 Diabetes TrialNet Study Group. Redondo MJ, et al. Diabetes Care. 2021 Sep;44(9):2039-2044. doi: 10.2337/dc21-0531. Epub 2021 Jul 29. Diabetes Care. 2021. PMID: 34326068 Free PMC article.

34

Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes.

Robertson CC, Inshaw JRJ, Onengut-Gumuscu S, Chen WM, Santa Cruz DF, Yang H, Cutler AJ, Crouch DJM, Farber E, Bridges SL Jr, Edberg JC, Kimberly RP, Buckner JH, Deloukas P, Divers J, Dabelea D, Lawrence JM, Marcovina S, Shah AS, Greenbaum CJ, Atkinson MA, Gregersen PK, Oksenberg JR, Pociot F, Rewers MJ, Steck AK, Dunger DB; Type 1 Diabetes Genetics Consortium; Wicker LS, Concannon P, Todd JA, Rich SS. Robertson CC, et al. Nat Genet. 2021 Jul;53(7):962-971. doi: 10.1038/s41588-021-00880-5. Epub 2021 Jun 14. Nat Genet. 2021. PMID: 34127860 Free PMC article.

35

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.

Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, Geyer SM, Moran A, Greenbaum CJ, Evans-Molina C, Herold KC; Type 1 Diabetes TrialNet Study Group. Sims EK, et al. Sci Transl Med. 2021 Mar 3;13(583):eabc8980. doi: 10.1126/scitranslmed.abc8980. Sci Transl Med. 2021. PMID: 33658358 Free PMC article. Clinical Trial.

36

Index60 as an additional diagnostic criterion for type 1 diabetes.

Redondo MJ, Nathan BM, Jacobsen LM, Sims E, Bocchino LE, Pugliese A, Schatz DA, Atkinson MA, Skyler J, Palmer J, Geyer S, Sosenko JM; Type 1 diabetes TrialNet Study Group. Redondo MJ, et al. Diabetologia. 2021 Apr;64(4):836-844. doi: 10.1007/s00125-020-05365-4. Epub 2021 Jan 26. Diabetologia. 2021. PMID: 33496819 Free PMC article.

37

Exocrine Pancreas Dysfunction in Type 1 Diabetes.

Foster TP, Bruggeman B, Campbell-Thompson M, Atkinson MA, Haller MJ, Schatz DA. Foster TP, et al. Endocr Pract. 2020 Dec;26(12):1505-1513. doi: 10.4158/EP-2020-0295. Endocr Pract. 2020. PMID: 33471743 Free PMC article. Review.

38

Exocrine Pancreatic Enzymes Are a Serological Biomarker for Type 1 Diabetes Staging and Pancreas Size.

Ross JJ, Wasserfall CH, Bacher R, Perry DJ, McGrail K, Posgai AL, Dong X, Muir A, Li X, Campbell-Thompson M, Brusko TM, Schatz DA, Haller MJ, Atkinson MA. Ross JJ, et al. Diabetes. 2021 Apr;70(4):944-954. doi: 10.2337/db20-0995. Epub 2021 Jan 13. Diabetes. 2021. PMID: 33441381 Free PMC article.

39

Gene Expression Analysis of the Pre-Diabetic Pancreas to Identify Pathogenic Mechanisms and Biomarkers of Type 1 Diabetes.

Yip L, Fuhlbrigge R, Alkhataybeh R, Fathman CG. Yip L, et al. Front Endocrinol (Lausanne). 2020 Dec 23;11:609271. doi: 10.3389/fendo.2020.609271. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33424774 Free PMC article.

40

Baseline Assessment of Circulating MicroRNAs Near Diagnosis of Type 1 Diabetes Predicts Future Stimulated Insulin Secretion.

Snowhite I, Pastori R, Sosenko J, Messinger Cayetano S, Pugliese A. Snowhite I, et al. Diabetes. 2021 Feb;70(2):638-651. doi: 10.2337/db20-0817. Epub 2020 Dec 4. Diabetes. 2021. PMID: 33277338 Free PMC article.

41

The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study.

Ismail HM, Cleves MA, Xu P, Libman IM, Becker DJ, Marks JB, Skyler JS, Palmer JP, Sosenko JM; Type 1 Diabetes TrialNet Study Group. Ismail HM, et al. Diabetes Care. 2020 Nov;43(11):2668-2674. doi: 10.2337/dc20-0701. Epub 2020 Sep 8. Diabetes Care. 2020. PMID: 32900788 Free PMC article.

42

One-Hour Oral Glucose Tolerance Tests for the Prediction and Diagnostic Surveillance of Type 1 Diabetes.

Simmons KM, Sosenko JM, Warnock M, Geyer S, Ismail HM, Elding Larsson H, Steck AK. Simmons KM, et al. J Clin Endocrinol Metab. 2020 Nov 1;105(11):e4094-101. doi: 10.1210/clinem/dgaa592. J Clin Endocrinol Metab. 2020. PMID: 32844178 Free PMC article.

43

Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes.

Jacobsen LM, Bundy BN, Greco MN, Schatz DA, Atkinson MA, Brusko TM, Mathews CE, Herold KC, Gitelman SE, Krischer JP, Haller MJ. Jacobsen LM, et al. Diabetes Technol Ther. 2020 Dec;22(12):948-953. doi: 10.1089/dia.2020.0305. Epub 2020 Oct 20. Diabetes Technol Ther. 2020. PMID: 32833543 Free PMC article.

44

Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes.

Edner NM, Heuts F, Thomas N, Wang CJ, Petersone L, Kenefeck R, Kogimtzis A, Ovcinnikovs V, Ross EM, Ntavli E, Elfaki Y, Eichmann M, Baptista R, Ambery P, Jermutus L, Peakman M, Rosenthal M, Walker LSK. Edner NM, et al. Nat Immunol. 2020 Oct;21(10):1244-1255. doi: 10.1038/s41590-020-0744-z. Epub 2020 Aug 3. Nat Immunol. 2020. PMID: 32747817 Free PMC article. Clinical Trial.

45

A quantitative measure of treatment response in recent-onset type 1 diabetes.

Bundy BN, Krischer JP; Type 1 Diabetes TrialNet Study Group. Bundy BN, et al. Endocrinol Diabetes Metab. 2020 May 14;3(3):e00143. doi: 10.1002/edm2.143. eCollection 2020 Jul. Endocrinol Diabetes Metab. 2020. PMID: 32704564 Free PMC article.

46

Response to Comment on So et al. Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals. Diabetes Care 2020;43:913-917.

So M, O'Rourke C, Bahnson HT, Greenbaum CJ, Speake C. So M, et al. Diabetes Care. 2020 Aug;43(8):e103-e104. doi: 10.2337/dci20-0016. Diabetes Care. 2020. PMID: 32669415 Free PMC article. No abstract available.

47

Multiplexing DNA methylation markers to detect circulating cell-free DNA derived from human pancreatic β cells.

Neiman D, Gillis D, Piyanzin S, Cohen D, Fridlich O, Moss J, Zick A, Oron T, Sundberg F, Forsander G, Skog O, Korsgren O, Levy-Khademi F, Arbel D, Hashavia S, Shapiro AMJ, Speake C, Greenbaum C, Hosford J, Posgai A, Atkinson MA, Glaser B, Schatz DA, Shemer R, Dor Y. Neiman D, et al. JCI Insight. 2020 Jul 23;5(14):e136579. doi: 10.1172/jci.insight.136579. JCI Insight. 2020. PMID: 32573495 Free PMC article.

48

The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis.

Tosur M, Cleves MA, Sosenko JM, Libman I, Baidal DA, Balasubramanyam A, Redondo MJ; Type 1 Diabetes TrialNet Study Group. Tosur M, et al. J Clin Endocrinol Metab. 2020 Dec 1;105(12):e4393-406. doi: 10.1210/clinem/dgaa348. J Clin Endocrinol Metab. 2020. PMID: 32502242 Free PMC article.

49

C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet.

Bogun MM, Bundy BN, Goland RS, Greenbaum CJ. Bogun MM, et al. Diabetes Care. 2020 Aug;43(8):1836-1842. doi: 10.2337/dc19-2288. Epub 2020 May 26. Diabetes Care. 2020. PMID: 32457058 Free PMC article.

50

Costimulation Blockade Disrupts CD4⁺ T Cell Memory Pathways and Uncouples Their Link to Decline in β-Cell Function in Type 1 Diabetes.

Eichmann M, Baptista R, Ellis RJ, Heck S, Peakman M, Beam CA. Eichmann M, et al. J Immunol. 2020 Jun 15;204(12):3129-3138. doi: 10.4049/jimmunol.1901439. Epub 2020 May 13. J Immunol. 2020. PMID: 32404353 Free PMC article.

51

GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells.

Arif S, Gomez-Tourino I, Kamra Y, Pujol-Autonell I, Hanton E, Tree T, Melandri D, Hull C, Wherrett DK, Beam C, Roep BO, Lorenc A, Peakman M. Arif S, et al. Diabetologia. 2020 Jun;63(6):1186-1198. doi: 10.1007/s00125-020-05130-7. Epub 2020 Apr 4. Diabetologia. 2020. PMID: 32248243 Free PMC article.

52

Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals.

So M, O'Rourke C, Bahnson HT, Greenbaum CJ, Speake C. So M, et al. Diabetes Care. 2020 Apr;43(4):913-917. doi: 10.2337/dc19-1731. Epub 2020 Feb 4. Diabetes Care. 2020. PMID: 32019856 Free PMC article.

53

Early and late C-peptide responses during oral glucose tolerance testing are oppositely predictive of type 1 diabetes in autoantibody-positive individuals.

Ismail HM, Becker DJ, Libman I, Herold KC, Redondo MJ, Atkinson MA, Cleves MA, Palmer J, Sosenko J; Diabetes Prevention Trial-Type 1 (DPT-1) Study Group. Ismail HM, et al. Diabetes Obes Metab. 2020 Jun;22(6):997-1000. doi: 10.1111/dom.13982. Epub 2020 Feb 27. Diabetes Obes Metab. 2020. PMID: 32003110 Free PMC article.

54

Clinical trial data validate the C-peptide estimate model in type 1 diabetes.

Wentworth JM, Bediaga NG, Gitelman SE, Evans-Molina C, Gottlieb PA, Colman PG, Haller MJ, Harrison LC. Wentworth JM, et al. Diabetologia. 2020 Apr;63(4):885-886. doi: 10.1007/s00125-020-05088-6. Epub 2020 Jan 26. Diabetologia. 2020. PMID: 31982961 Free PMC article. No abstract available.

55

Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents.

Ferrara-Cook C, Geyer SM, Evans-Molina C, Libman IM, Becker DJ, Gitelman SE, Redondo MJ; Type 1 Diabetes TrialNet Study Group. Ferrara-Cook C, et al. Diabetes Care. 2020 Mar;43(3):580-587. doi: 10.2337/dc19-1167. Epub 2020 Jan 14. Diabetes Care. 2020. PMID: 31937610 Free PMC article.

56

Single Islet Autoantibody at Diagnosis of Clinical Type 1 Diabetes is Associated With Older Age and Insulin Resistance.

Redondo MJ, Sosenko J, Libman I, McVean JJF, Tosur M, Atkinson MA, Becker D, Geyer S. Redondo MJ, et al. J Clin Endocrinol Metab. 2020 May 1;105(5):1629-40. doi: 10.1210/clinem/dgz296. J Clin Endocrinol Metab. 2020. PMID: 31867614 Free PMC article.

57

Reduced PD-1 expression on circulating follicular and conventional FOXP3⁺ Treg cells in children with new onset type 1 diabetes and autoantibody-positive at-risk children.

Vecchione A, Di Fonte R, Gerosa J, Jofra T, Cicalese MP, Napoleone V, Ippolito E, Galvani G, Ragogna F, Stabilini A, Bianconi E, Grogan P, Bonura C, Bonfanti R, Frontino G, Nano R, Melzi R, De Pellegrin M, Laurenzi A, Meschi F, Barera G, Rigamonti A, Indirli R, Bosi E, Piemonti L, Aiuti A, Battaglia M, Fousteri G. Vecchione A, et al. Clin Immunol. 2020 Feb;211:108319. doi: 10.1016/j.clim.2019.108319. Epub 2019 Nov 30. Clin Immunol. 2020. PMID: 31794865

58

The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening.

Jacobsen LM, Bocchino L, Evans-Molina C, DiMeglio L, Goland R, Wilson DM, Atkinson MA, Aye T, Russell WE, Wentworth JM, Boulware D, Geyer S, Sosenko JM. Jacobsen LM, et al. Diabetologia. 2020 Mar;63(3):588-596. doi: 10.1007/s00125-019-05047-w. Epub 2019 Nov 25. Diabetologia. 2020. PMID: 31768570 Free PMC article.

59

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.

Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L, Krischer JP, Long SA, Lundgren M, McKinney EF, Morgan NG, Oram RA, Pastinen T, Peters MC, Petrelli A, Qian X, Redondo MJ, Roep BO, Schatz D, Skibinski D, Peakman M. Battaglia M, et al. Diabetes Care. 2020 Jan;43(1):5-12. doi: 10.2337/dc19-0880. Epub 2019 Nov 21. Diabetes Care. 2020. PMID: 31753960 Free PMC article.

60

Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention.

Sims EK, Geyer S, Johnson SB, Libman I, Jacobsen LM, Boulware D, Rafkin LE, Matheson D, Atkinson MA, Rodriguez H, Spall M, Elding Larsson H, Wherrett DK, Greenbaum CJ, Krischer J, DiMeglio LA; Type 1 Diabetes TrialNet Study Group. Sims EK, et al. Diabetes Care. 2019 Dec;42(12):2228-2236. doi: 10.2337/dc19-0593. Epub 2019 Sep 26. Diabetes Care. 2019. PMID: 31558546 Free PMC article.

61

In-vivo assessment of T cell kinetics in individuals at risk for type 1 diabetes.

Hao W, Bahnson HT, Speake C, Cerosaletti K, Greenbaum CJ. Hao W, et al. Clin Exp Immunol. 2020 Jan;199(1):50-55. doi: 10.1111/cei.13375. Epub 2019 Oct 7. Clin Exp Immunol. 2020. PMID: 31557315 Free PMC article. Clinical Trial.

62

Serum miR-204 is an early biomarker of type 1 diabetes-associated pancreatic beta-cell loss.

Xu G, Thielen LA, Chen J, Grayson TB, Grimes T, Bridges SL Jr, Tse HM, Smith B, Patel R, Li P, Evans-Molina C, Ovalle F, Shalev A. Xu G, et al. Am J Physiol Endocrinol Metab. 2019 Oct 1;317(4):E723-E730. doi: 10.1152/ajpendo.00122.2019. Epub 2019 Aug 13. Am J Physiol Endocrinol Metab. 2019. PMID: 31408375 Free PMC article.

63

Unmethylated Insulin as an Adjunctive Marker of Beta Cell Death and Progression to Type 1 Diabetes in Participants at Risk for Diabetes.

Simmons KM, Fouts A, Pyle L, Clark P, Dong F, Yu L, Usmani-Brown S, Gottlieb P, Herold KC, Steck AK; Type 1 Diabetes TrialNet Study Group. Simmons KM, et al. Int J Mol Sci. 2019 Aug 8;20(16):3857. doi: 10.3390/ijms20163857. Int J Mol Sci. 2019. PMID: 31398795 Free PMC article.

64

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. Herold KC, et al. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9. N Engl J Med. 2019. PMID: 31180194 Free PMC article. Clinical Trial.

65

Autoantibodies Directed Toward a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes.

Acevedo-Calado MJ, Pietropaolo SL, Morran MP, Schnell S, Vonberg AD, Verge CF, Gianani R, Becker DJ, Huang S, Greenbaum CJ, Yu L, Davidson HW, Michels AW, Rich SS, Pietropaolo M; Type 1 Diabetes TrialNet Study Group. Acevedo-Calado MJ, et al. Diabetes. 2019 Sep;68(9):1819-1829. doi: 10.2337/db18-1351. Epub 2019 Jun 5. Diabetes. 2019. PMID: 31167877 Free PMC article.

66

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA_1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.

Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group. Haller MJ, et al. Diabetes. 2019 Jun;68(6):1267-1276. doi: 10.2337/db19-0057. Epub 2019 Apr 9. Diabetes. 2019. PMID: 30967424 Free PMC article. Clinical Trial.

67

Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression.

Habib T, Long SA, Samuels PL, Brahmandam A, Tatum M, Funk A, Hocking AM, Cerosaletti K, Mason MT, Whalen E, Rawlings DJ, Greenbaum C, Buckner JH; Type 1 Diabetes TrialNet Study Group. Habib T, et al. Diabetes. 2019 Jun;68(6):1240-1250. doi: 10.2337/db18-1081. Epub 2019 Mar 20. Diabetes. 2019. PMID: 30894366 Free PMC article.

68

Associations of HbA1c with the timing of C-peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes.

Ismail HM, Evans-Molina C, DiMeglio LA, Becker DJ, Libman I, Sims EK, Boulware D, Herold KC, Rafkin L, Skyler J, Cleves MA, Palmer J, Sosenko JM; Type 1 Diabetes Trial Net and Diabetes Prevention Trial-Type-1 (DPT-1) Study Groups. Ismail HM, et al. Pediatr Diabetes. 2019 Jun;20(4):408-413. doi: 10.1111/pedi.12845. Epub 2019 Apr 15. Pediatr Diabetes. 2019. PMID: 30891858 Free PMC article.

69

B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.

Linsley PS, Greenbaum CJ, Speake C, Long SA, Dufort MJ. Linsley PS, et al. JCI Insight. 2019 Feb 21;4(4):e126136. doi: 10.1172/jci.insight.126136. eCollection 2019 Feb 21. JCI Insight. 2019. PMID: 30830871 Free PMC article.

70

Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes.

Dufort MJ, Greenbaum CJ, Speake C, Linsley PS. Dufort MJ, et al. JCI Insight. 2019 Feb 21;4(4):e125556. doi: 10.1172/jci.insight.125556. eCollection 2019 Feb 21. JCI Insight. 2019. PMID: 30830868 Free PMC article.

71

A novel platform for isotype-specific testing of autoantibodies.

Carter KL, Treurnicht A, Davis KL, Kumar RB, Feldman BJ. Carter KL, et al. PLoS One. 2019 Feb 7;14(2):e0211596. doi: 10.1371/journal.pone.0211596. eCollection 2019. PLoS One. 2019. PMID: 30730939 Free PMC article.

72

Association of HLA-dependent islet autoimmunity with systemic antibody responses to intestinal commensal bacteria in children.

Paun A, Yau C, Meshkibaf S, Daigneault MC, Marandi L, Mortin-Toth S, Bar-Or A, Allen-Vercoe E, Poussier P, Danska JS. Paun A, et al. Sci Immunol. 2019 Feb 1;4(32):eaau8125. doi: 10.1126/sciimmunol.aau8125. Sci Immunol. 2019. PMID: 30709843 Free PMC article.

73

Improving quality of the informed consent process: Developing an easy-to-read, multimodal, patient-centered format in a real-world setting.

Lindsley KA. Lindsley KA. Patient Educ Couns. 2019 May;102(5):944-951. doi: 10.1016/j.pec.2018.12.022. Epub 2018 Dec 21. Patient Educ Couns. 2019. PMID: 30635222 Free PMC article. Clinical Trial.

74

Analysis of serum Hsp90 as a potential biomarker of β cell autoimmunity in type 1 diabetes.

Ocaña GJ, Sims EK, Watkins RA, Ragg S, Mather KJ, Oram RA, Mirmira RG, DiMeglio LA, Blum JS, Evans-Molina C. Ocaña GJ, et al. PLoS One. 2019 Jan 10;14(1):e0208456. doi: 10.1371/journal.pone.0208456. eCollection 2019. PLoS One. 2019. PMID: 30629603 Free PMC article.

75

Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice.

Greenbaum C, VanBuecken D, Lord S. Greenbaum C, et al. Drugs. 2019 Jan;79(1):43-61. doi: 10.1007/s40265-018-1035-y. Drugs. 2019. PMID: 30612319 Free PMC article. Review.

76

Pancreas Volume Declines During the First Year After Diagnosis of Type 1 Diabetes and Exhibits Altered Diffusion at Disease Onset.

Virostko J, Williams J, Hilmes M, Bowman C, Wright JJ, Du L, Kang H, Russell WE, Powers AC, Moore DJ. Virostko J, et al. Diabetes Care. 2019 Feb;42(2):248-257. doi: 10.2337/dc18-1507. Epub 2018 Dec 14. Diabetes Care. 2019. PMID: 30552135 Free PMC article. Clinical Trial.

77

Relative Pancreas Volume Is Reduced in First-Degree Relatives of Patients With Type 1 Diabetes.

Campbell-Thompson ML, Filipp SL, Grajo JR, Nambam B, Beegle R, Middlebrooks EH, Gurka MJ, Atkinson MA, Schatz DA, Haller MJ. Campbell-Thompson ML, et al. Diabetes Care. 2019 Feb;42(2):281-287. doi: 10.2337/dc18-1512. Epub 2018 Dec 14. Diabetes Care. 2019. PMID: 30552130 Free PMC article.

78

Abnormal T Cell Frequencies, Including Cytomegalovirus-Associated Expansions, Distinguish Seroconverted Subjects at Risk for Type 1 Diabetes.

Harms RZ, Lorenzo-Arteaga KM, Ostlund KR, Smith VB, Smith LM, Gottlieb P, Sarvetnick N. Harms RZ, et al. Front Immunol. 2018 Oct 22;9:2332. doi: 10.3389/fimmu.2018.02332. eCollection 2018. Front Immunol. 2018. PMID: 30405601 Free PMC article.

79

Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes.

Redondo MJ, Steck AK, Sosenko J, Anderson M, Antinozzi P, Michels A, Wentworth JM, Atkinson MA, Pugliese A, Geyer S; Type 1 Diabetes TrialNet Study Group. Redondo MJ, et al. Diabetes Care. 2018 Dec;41(12):2480-2486. doi: 10.2337/dc18-0861. Epub 2018 Oct 1. Diabetes Care. 2018. PMID: 30275285 Free PMC article.

80

Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes.

Vecchio F, Lo Buono N, Stabilini A, Nigi L, Dufort MJ, Geyer S, Rancoita PM, Cugnata F, Mandelli A, Valle A, Leete P, Mancarella F, Linsley PS, Krogvold L, Herold KC, Elding Larsson H, Richardson SJ, Morgan NG, Dahl-Jørgensen K, Sebastiani G, Dotta F, Bosi E; DRI_Biorepository Group; Type 1 Diabetes TrialNet Study Group; Battaglia M. Vecchio F, et al. JCI Insight. 2018 Sep 20;3(18):e122146. doi: 10.1172/jci.insight.122146. eCollection 2018 Sep 20. JCI Insight. 2018. PMID: 30232284 Free PMC article.

81

Innate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetes.

Cabrera SM, Engle S, Kaldunski M, Jia S, Geoffrey R, Simpson P, Szabo A, Speake C, Greenbaum CJ; Type 1 Diabetes TrialNet CTLA4-Ig (Abatacept) Study Group; Chen YG, Hessner MJ. Cabrera SM, et al. Diabetologia. 2018 Nov;61(11):2356-2370. doi: 10.1007/s00125-018-4708-x. Epub 2018 Aug 30. Diabetologia. 2018. PMID: 30167736 Free PMC article.

82

Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables.

Wentworth JM, Bediaga NG, Giles LC, Ehlers M, Gitelman SE, Geyer S, Evans-Molina C, Harrison LC; Type 1 Diabetes TrialNet Study Group; Immune Tolerance Network Study Group. Wentworth JM, et al. Diabetologia. 2019 Jan;62(1):33-40. doi: 10.1007/s00125-018-4722-z. Epub 2018 Aug 30. Diabetologia. 2019. PMID: 30167735 Free PMC article. Review.

83

Intestinal Metaproteomics Reveals Host-Microbiota Interactions in Subjects at Risk for Type 1 Diabetes.

Gavin PG, Mullaney JA, Loo D, Cao KL, Gottlieb PA, Hill MM, Zipris D, Hamilton-Williams EE. Gavin PG, et al. Diabetes Care. 2018 Oct;41(10):2178-2186. doi: 10.2337/dc18-0777. Epub 2018 Aug 12. Diabetes Care. 2018. PMID: 30100563 Free PMC article.

84

β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis.

Evans-Molina C, Sims EK, DiMeglio LA, Ismail HM, Steck AK, Palmer JP, Krischer JP, Geyer S, Xu P, Sosenko JM; Type 1 Diabetes TrialNet Study Group. Evans-Molina C, et al. JCI Insight. 2018 Aug 9;3(15):e120877. doi: 10.1172/jci.insight.120877. eCollection 2018 Aug 9. JCI Insight. 2018. PMID: 30089716 Free PMC article.

85

Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes.

Triolo TM, Fouts A, Pyle L, Yu L, Gottlieb PA, Steck AK; Type 1 Diabetes TrialNet Study Group. Triolo TM, et al. Diabetes Care. 2019 Feb;42(2):192-199. doi: 10.2337/dc18-0288. Epub 2018 Jul 30. Diabetes Care. 2019. PMID: 30061316 Free PMC article. Clinical Trial.

86

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA_1c in New-Onset Type 1 Diabetes.

Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group. Haller MJ, et al. Diabetes Care. 2018 Sep;41(9):1917-1925. doi: 10.2337/dc18-0494. Epub 2018 Jul 16. Diabetes Care. 2018. PMID: 30012675 Free PMC article. Clinical Trial.

87

A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk.

Redondo MJ, Geyer S, Steck AK, Sharp S, Wentworth JM, Weedon MN, Antinozzi P, Sosenko J, Atkinson M, Pugliese A, Oram RA; Type 1 Diabetes TrialNet Study Group. Redondo MJ, et al. Diabetes Care. 2018 Sep;41(9):1887-1894. doi: 10.2337/dc18-0087. Epub 2018 Jul 12. Diabetes Care. 2018. PMID: 30002199 Free PMC article.

88

Learning From Past Failures of Oral Insulin Trials.

Michels AW, Gottlieb PA. Michels AW, et al. Diabetes. 2018 Jul;67(7):1211-1215. doi: 10.2337/dbi17-0043. Diabetes. 2018. PMID: 29934364 Free PMC article.

89

Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk.

Tosur M, Geyer SM, Rodriguez H, Libman I, Baidal DA, Redondo MJ; Type 1 Diabetes TrialNet Study Group. Tosur M, et al. Diabetologia. 2018 Sep;61(9):2043-2053. doi: 10.1007/s00125-018-4660-9. Epub 2018 Jun 21. Diabetologia. 2018. PMID: 29931415 Free PMC article.

90

Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes.

Linsley PS, Greenbaum CJ, Rosasco M, Presnell S, Herold KC, Dufort MJ. Linsley PS, et al. Genes Immun. 2019 Apr;20(4):293-307. doi: 10.1038/s41435-018-0032-1. Epub 2018 Jun 21. Genes Immun. 2019. PMID: 29925930 Free PMC article. Clinical Trial.

91

Autoreactive T effector memory differentiation mirrors β cell function in type 1 diabetes.

Yeo L, Woodwyk A, Sood S, Lorenc A, Eichmann M, Pujol-Autonell I, Melchiotti R, Skowera A, Fidanis E, Dolton GM, Tungatt K, Sewell AK, Heck S, Saxena A, Beam CA, Peakman M. Yeo L, et al. J Clin Invest. 2018 Aug 1;128(8):3460-3474. doi: 10.1172/JCI120555. Epub 2018 Jul 16. J Clin Invest. 2018. PMID: 29851415 Free PMC article. Clinical Trial.

92

Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.

Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC, Atkinson MA. Greenbaum CJ, et al. Diabetes. 2018 Jul;67(7):1216-1225. doi: 10.2337/db18-0065. Epub 2018 May 16. Diabetes. 2018. PMID: 29769238 Free PMC article.

93

Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes.

Bingley PJ, Wherrett DK, Shultz A, Rafkin LE, Atkinson MA, Greenbaum CJ. Bingley PJ, et al. Diabetes Care. 2018 Apr;41(4):653-661. doi: 10.2337/dc17-0806. Diabetes Care. 2018. PMID: 29559451 Free PMC article.

94

Islet-reactive CD8⁺ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors.

Culina S, Lalanne AI, Afonso G, Cerosaletti K, Pinto S, Sebastiani G, Kuranda K, Nigi L, Eugster A, Østerbye T, Maugein A, McLaren JE, Ladell K, Larger E, Beressi JP, Lissina A, Appay V, Davidson HW, Buus S, Price DA, Kuhn M, Bonifacio E, Battaglia M, Caillat-Zucman S, Dotta F, Scharfmann R, Kyewski B, Mallone R; ImMaDiab Study Group. Culina S, et al. Sci Immunol. 2018 Feb 2;3(20):eaao4013. doi: 10.1126/sciimmunol.aao4013. Sci Immunol. 2018. PMID: 29429978 Free PMC article.

95

Loss of B-Cell Anergy in Type 1 Diabetes Is Associated With High-Risk HLA and Non-HLA Disease Susceptibility Alleles.

Smith MJ, Rihanek M, Wasserfall C, Mathews CE, Atkinson MA, Gottlieb PA, Cambier JC. Smith MJ, et al. Diabetes. 2018 Apr;67(4):697-703. doi: 10.2337/db17-0937. Epub 2018 Jan 17. Diabetes. 2018. PMID: 29343548 Free PMC article.

96

The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1.

Sosenko JM, Geyer S, Skyler JS, Rafkin LE, Ismail HM, Libman IM, Liu YF, DiMeglio LA, Evans-Molina C, Palmer JP. Sosenko JM, et al. Pediatr Diabetes. 2018 May;19(3):403-409. doi: 10.1111/pedi.12609. Epub 2017 Nov 24. Pediatr Diabetes. 2018. PMID: 29171129 Free PMC article. Clinical Trial.

97

Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.

Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group; Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ. Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, et al. JAMA. 2017 Nov 21;318(19):1891-1902. doi: 10.1001/jama.2017.17070. JAMA. 2017. PMID: 29164254 Free PMC article. Clinical Trial.

98

The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults.

Ferrara CT, Geyer SM, Evans-Molina C, Libman IM, Becker DJ, Wentworth JM, Moran A, Gitelman SE, Redondo MJ; Type 1 Diabetes TrialNet Study Group. Ferrara CT, et al. J Clin Endocrinol Metab. 2017 Dec 1;102(12):4596-4603. doi: 10.1210/jc.2017-01490. J Clin Endocrinol Metab. 2017. PMID: 29092051 Free PMC article.

99

Assessment of β Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes.

Hao W, Woodwyk A, Beam C, Bahnson HT, Palmer JP, Greenbaum CJ. Hao W, et al. J Clin Endocrinol Metab. 2017 Dec 1;102(12):4428-4434. doi: 10.1210/jc.2017-01713. J Clin Endocrinol Metab. 2017. PMID: 29040630 Free PMC article.

100

TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes.

Redondo MJ, Geyer S, Steck AK, Sosenko J, Anderson M, Antinozzi P, Michels A, Wentworth J, Xu P, Pugliese A; Type 1 Diabetes TrialNet Study Group. Redondo MJ, et al. Diabetes Care. 2018 Feb;41(2):311-317. doi: 10.2337/dc17-0961. Epub 2017 Oct 12. Diabetes Care. 2018. PMID: 29025879 Free PMC article.

101

Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes.

Rouxel O, Da Silva J, Beaudoin L, Nel I, Tard C, Cagninacci L, Kiaf B, Oshima M, Diedisheim M, Salou M, Corbett A, Rossjohn J, McCluskey J, Scharfmann R, Battaglia M, Polak M, Lantz O, Beltrand J, Lehuen A. Rouxel O, et al. Nat Immunol. 2017 Dec;18(12):1321-1331. doi: 10.1038/ni.3854. Epub 2017 Oct 9. Nat Immunol. 2017. PMID: 28991267 Free PMC article.

102

The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes.

Ismail HM, Xu P, Libman IM, Becker DJ, Marks JB, Skyler JS, Palmer JP, Sosenko JM; Type 1 Diabetes TrialNet Study Group. Ismail HM, et al. Diabetologia. 2018 Jan;61(1):84-92. doi: 10.1007/s00125-017-4453-6. Epub 2017 Sep 27. Diabetologia. 2018. PMID: 28956083 Free PMC article.

103

Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.

Nathan BM, Boulware D, Geyer S, Atkinson MA, Colman P, Goland R, Russell W, Wentworth JM, Wilson DM, Evans-Molina C, Wherrett D, Skyler JS, Moran A, Sosenko JM; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. Nathan BM, et al. Diabetes Care. 2017 Nov;40(11):1494-1499. doi: 10.2337/dc17-0916. Epub 2017 Aug 31. Diabetes Care. 2017. PMID: 28860125 Free PMC article.

104

Impact of blood collection and processing on peripheral blood gene expression profiling in type 1 diabetes.

Yip L, Fuhlbrigge R, Atkinson MA, Fathman CG. Yip L, et al. BMC Genomics. 2017 Aug 18;18(1):636. doi: 10.1186/s12864-017-3949-2. BMC Genomics. 2017. PMID: 28821222 Free PMC article.

105

Understanding and preventing type 1 diabetes through the unique working model of TrialNet.

Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M. Battaglia M, et al. Diabetologia. 2017 Nov;60(11):2139-2147. doi: 10.1007/s00125-017-4384-2. Epub 2017 Aug 2. Diabetologia. 2017. PMID: 28770323 Free PMC article. Review.

106

Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests.

Sanda S; Type 1 Diabetes TrialNet Study Group. Sanda S, et al. Pediatr Diabetes. 2018 Mar;19(2):271-276. doi: 10.1111/pedi.12542. Epub 2017 Jul 14. Pediatr Diabetes. 2018. PMID: 28707353 Free PMC article.

107

Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives.

Bosi E, Boulware DC, Becker DJ, Buckner JH, Geyer S, Gottlieb PA, Henderson C, Kinderman A, Sosenko JM, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group. Bosi E, et al. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2881-2886. doi: 10.1210/jc.2017-00569. J Clin Endocrinol Metab. 2017. PMID: 28531305 Free PMC article.

108

Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?

Steck AK, Xu P, Geyer S, Redondo MJ, Antinozzi P, Wentworth JM, Sosenko J, Onengut-Gumuscu S, Chen WM, Rich SS, Pugliese A; Type 1 Diabetes TrialNet Study Group. Steck AK, et al. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2873-2880. doi: 10.1210/jc.2016-4003. J Clin Endocrinol Metab. 2017. PMID: 28520980 Free PMC article.

109

Association of serum microRNAs with islet autoimmunity, disease progression and metabolic impairment in relatives at risk of type 1 diabetes.

Snowhite IV, Allende G, Sosenko J, Pastori RL, Messinger Cayetano S, Pugliese A. Snowhite IV, et al. Diabetologia. 2017 Aug;60(8):1409-1422. doi: 10.1007/s00125-017-4294-3. Epub 2017 May 12. Diabetologia. 2017. PMID: 28500393 Free PMC article.

110

Use of self-collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study.

Liu Y, Rafkin LE, Matheson D, Henderson C, Boulware D, Besser REJ, Ferrara C, Yu L, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group. Liu Y, et al. Diabet Med. 2017 Jul;34(7):934-937. doi: 10.1111/dme.13338. Epub 2017 Mar 8. Diabet Med. 2017. PMID: 28226181 Free PMC article.

111

Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?

Ferrara CT, Geyer SM, Liu YF, Evans-Molina C, Libman IM, Besser R, Becker DJ, Rodriguez H, Moran A, Gitelman SE, Redondo MJ; Type 1 Diabetes TrialNet Study Group. Ferrara CT, et al. Diabetes Care. 2017 May;40(5):698-701. doi: 10.2337/dc16-2331. Epub 2017 Feb 15. Diabetes Care. 2017. PMID: 28202550 Free PMC article.

112

The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies.

Sosenko JM, Yu L, Skyler JS, Krischer JP, Gottlieb PA, Boulware D, Miao D, Palmer JP, Steck AK. Sosenko JM, et al. Diabetes Technol Ther. 2017 Mar;19(3):183-187. doi: 10.1089/dia.2016.0243. Epub 2017 Feb 8. Diabetes Technol Ther. 2017. PMID: 28177779 Free PMC article.

113

Pre-diagnostic genotyping identifies T1D subjects with impaired Treg IL-2 signaling and an elevated proportion of FOXP3⁺IL-17⁺ cells.

Marwaha AK, Panagiotopoulos C, Biggs CM, Staiger S, Del Bel KL, Hirschfeld AF, Priatel JJ, Turvey SE, Tan R. Marwaha AK, et al. Genes Immun. 2017 Jan;18(1):15-21. doi: 10.1038/gene.2016.44. Epub 2017 Jan 5. Genes Immun. 2017. PMID: 28053319 Free PMC article.

114

A model-based approach to sample size estimation in recent onset type 1 diabetes.

Bundy BN, Krischer JP; Type 1 Diabetes TrialNet Study Group. Bundy BN, et al. Diabetes Metab Res Rev. 2016 Nov;32(8):827-834. doi: 10.1002/dmrr.2800. Epub 2016 Apr 21. Diabetes Metab Res Rev. 2016. PMID: 26991448 Free PMC article.

115

GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis.

Beam CA, MacCallum C, Herold KC, Wherrett DK, Palmer J, Ludvigsson J; Type 1 Diabetes TrialNet Study Group. Beam CA, et al. Diabetologia. 2017 Jan;60(1):43-49. doi: 10.1007/s00125-016-4122-1. Epub 2016 Oct 4. Diabetologia. 2017. PMID: 27704166 Free PMC article.

116

The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus.

Durning SP, Preston-Hurlburt P, Clark PR, Xu D, Herold KC; Type 1 Diabetes TrialNet Study Group. Durning SP, et al. J Immunol. 2016 Oct 15;197(8):3076-3085. doi: 10.4049/jimmunol.1600197. Epub 2016 Sep 21. J Immunol. 2016. PMID: 27655844 Free PMC article.

117

Data on correlations between T cell subset frequencies and length of partial remission in type 1 diabetes.

Narsale A, Moya R, Robertson HK; Type 1Diabetes TrialNet Study Group; Davies JD. Narsale A, et al. Data Brief. 2016 Aug 6;8:1348-51. doi: 10.1016/j.dib.2016.07.059. eCollection 2016 Sep. Data Brief. 2016. PMID: 27579340 Free PMC article.

118

Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?

Fouts A, Pyle L, Yu L, Miao D, Michels A, Krischer J, Sosenko J, Gottlieb P, Steck AK; Type 1 Diabetes TrialNet Study Group. Fouts A, et al. Diabetes Care. 2016 Oct;39(10):1738-44. doi: 10.2337/dc16-0302. Epub 2016 Jul 25. Diabetes Care. 2016. PMID: 27456836 Free PMC article.

119

Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose.

Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. Hao W, et al. Diabetes Care. 2016 Oct;39(10):1664-70. doi: 10.2337/dc16-0360. Epub 2016 Jul 15. Diabetes Care. 2016. PMID: 27422577 Free PMC article.

120

Elevations in the Fasting Serum Proinsulin-to-C-Peptide Ratio Precede the Onset of Type 1 Diabetes.

Sims EK, Chaudhry Z, Watkins R, Syed F, Blum J, Ouyang F, Perkins SM, Mirmira RG, Sosenko J, DiMeglio LA, Evans-Molina C. Sims EK, et al. Diabetes Care. 2016 Sep;39(9):1519-26. doi: 10.2337/dc15-2849. Epub 2016 Jul 6. Diabetes Care. 2016. PMID: 27385327 Free PMC article. Clinical Trial.

121

Staging the progression to type 1 diabetes with prediagnostic markers.

Sosenko JM. Sosenko JM. Curr Opin Endocrinol Diabetes Obes. 2016 Aug;23(4):297-305. doi: 10.1097/MED.0000000000000267. Curr Opin Endocrinol Diabetes Obes. 2016. PMID: 27362539 Free PMC article. Review.

122

Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes-A Recursive Partitioning Analysis.

Xu P, Krischer JP; Type 1 Diabetes TrialNet Study Group. Xu P, et al. Diabetes Care. 2016 Jun;39(6):1036-44. doi: 10.2337/dc15-2292. Epub 2016 Apr 12. Diabetes Care. 2016. PMID: 27208341 Free PMC article.

123

A pilot study showing associations between frequency of CD4(+) memory cell subsets at diagnosis and duration of partial remission in type 1 diabetes.

Moya R, Robertson HK, Payne D, Narsale A, Koziol J; Type 1 Diabetes TrialNet Study Group; Davies JD. Moya R, et al. Clin Immunol. 2016 May;166-167:72-80. doi: 10.1016/j.clim.2016.04.012. Epub 2016 Apr 22. Clin Immunol. 2016. PMID: 27114212 Free PMC article.

124

The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants.

Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P, Evans-Molina C; Type 1 Diabetes TrialNet Study Group. Meah FA, et al. Diabetologia. 2016 Jun;59(6):1186-95. doi: 10.1007/s00125-016-3924-5. Epub 2016 Mar 19. Diabetologia. 2016. PMID: 26995649 Free PMC article.

125

ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study.

Steck AK, Fouts A, Miao D, Zhao Z, Dong F, Sosenko J, Gottlieb P, Rewers MJ, Yu L; TrialNet Study Group. Steck AK, et al. Diabetes Technol Ther. 2016 Jul;18(7):410-4. doi: 10.1089/dia.2015.0316. Epub 2016 Mar 18. Diabetes Technol Ther. 2016. PMID: 26991969 Free PMC article.

126

Effects of Frequency of Sensor-Augmented Pump Use on HbA1c and C-Peptide Levels in the First Year of Type 1 Diabetes.

Triolo TM, Maahs DM, Pyle L, Slover R, Buckingham B, Cheng P, DiMeglio LA, Bremer AA, Weinzimer SA, Chase HP; Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups. Triolo TM, et al. Diabetes Care. 2016 Apr;39(4):e61-2. doi: 10.2337/dc15-2201. Epub 2016 Feb 19. Diabetes Care. 2016. PMID: 26895885 Free PMC article. No abstract available.

127

HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression.

Pugliese A, Boulware D, Yu L, Babu S, Steck AK, Becker D, Rodriguez H, DiMeglio L, Evans-Molina C, Harrison LC, Schatz D, Palmer JP, Greenbaum C, Eisenbarth GS, Sosenko JM; Type 1 Diabetes TrialNet Study Group. Pugliese A, et al. Diabetes. 2016 Apr;65(4):1109-19. doi: 10.2337/db15-1105. Epub 2016 Jan 28. Diabetes. 2016. PMID: 26822082 Free PMC article.

128

Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.

Cabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ; Type 1 Diabetes TrialNet Canakinumab Study Group; Mandrup-Poulsen T; AIDA Study Group; Hessner MJ. Cabrera SM, et al. Eur J Immunol. 2016 Apr;46(4):1030-46. doi: 10.1002/eji.201546005. Epub 2016 Jan 21. Eur J Immunol. 2016. PMID: 26692253 Free PMC article. Clinical Trial.

129

The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes.

Bingley PJ, Boulware DC, Krischer JP; Type 1 Diabetes TrialNet Study Group. Bingley PJ, et al. Diabetologia. 2016 Mar;59(3):542-9. doi: 10.1007/s00125-015-3830-2. Epub 2015 Dec 16. Diabetologia. 2016. PMID: 26676824 Free PMC article.

130

Rituximab does not reset defective early B cell tolerance checkpoints.

Chamberlain N, Massad C, Oe T, Cantaert T, Herold KC, Meffre E. Chamberlain N, et al. J Clin Invest. 2016 Jan;126(1):282-7. doi: 10.1172/JCI83840. Epub 2015 Dec 7. J Clin Invest. 2016. PMID: 26642366 Free PMC article.

131

Antibody Response to Serpin B13 Induces Adaptive Changes in Mouse Pancreatic Islets and Slows Down the Decline in the Residual Beta Cell Function in Children with Recent Onset of Type 1 Diabetes Mellitus.

Kryvalap Y, Lo CW, Manuylova E, Baldzizhar R, Jospe N, Czyzyk J. Kryvalap Y, et al. J Biol Chem. 2016 Jan 1;291(1):266-78. doi: 10.1074/jbc.M115.687848. Epub 2015 Nov 17. J Biol Chem. 2016. PMID: 26578518 Free PMC article.

132

Use of Dried Capillary Blood Sampling for Islet Autoantibody Screening in Relatives: A Feasibility Study.

Bingley PJ, Rafkin LE, Matheson D, Steck AK, Yu L, Henderson C, Beam CA, Boulware DC; TrialNet Study Group. Bingley PJ, et al. Diabetes Technol Ther. 2015 Dec;17(12):867-71. doi: 10.1089/dia.2015.0133. Epub 2015 Sep 16. Diabetes Technol Ther. 2015. PMID: 26375197 Free PMC article.

133

Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders.

Loechelt BJ, Green M, Gottlieb PA, Blumberg E, Weinberg A, Quinlan S, Baden LR; Type 1 Diabetes TrialNet Study Group. Loechelt BJ, et al. J Pediatric Infect Dis Soc. 2015 Sep;4(3):198-204. doi: 10.1093/jpids/piu055. Epub 2014 Jun 26. J Pediatric Infect Dis Soc. 2015. PMID: 26336066 Free PMC article.

134

The development, validation, and utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS).

Sosenko JM, Skyler JS, Palmer JP; Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Sosenko JM, et al. Curr Diab Rep. 2015 Aug;15(8):49. doi: 10.1007/s11892-015-0626-1. Curr Diab Rep. 2015. PMID: 26077017 Free PMC article. Review.

135

Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes.

Alkanani AK, Hara N, Gottlieb PA, Ir D, Robertson CE, Wagner BD, Frank DN, Zipris D. Alkanani AK, et al. Diabetes. 2015 Oct;64(10):3510-20. doi: 10.2337/db14-1847. Epub 2015 Jun 11. Diabetes. 2015. PMID: 26068542 Free PMC article.

136

CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes.

Buckingham B, Cheng P, Beck RW, Kollman C, Ruedy KJ, Weinzimer SA, Slover R, Bremer AA, Fuqua J, Tamborlane W; Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups. Buckingham B, et al. Diabetologia. 2015 Jun;58(6):1167-74. doi: 10.1007/s00125-015-3559-y. Epub 2015 Mar 14. Diabetologia. 2015. PMID: 25773405 Free PMC article. Clinical Trial.

137

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. Sosenko JM, et al. Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10. Diabetes Care. 2015. PMID: 25758770 Free PMC article.

138

Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes.

DiMeglio LA, Cheng P, Beck RW, Kollman C, Ruedy KJ, Slover R, Aye T, Weinzimer SA, Bremer AA, Buckingham B; Diabetes Research in Children Network (DirecNet); Type 1 Diabetes TrialNet Study Group. DiMeglio LA, et al. Pediatr Diabetes. 2016 Jun;17(4):237-43. doi: 10.1111/pedi.12271. Epub 2015 Feb 27. Pediatr Diabetes. 2016. PMID: 25720763 Free PMC article. Clinical Trial.

139

The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose Tolerance.

Hao W, Greenbaum CJ, Krischer JP, Cuthbertson D, Marks JB, Palmer JP. Hao W, et al. Diabetes Care. 2015 May;38(5):891-6. doi: 10.2337/dc14-1825. Epub 2015 Feb 26. Diabetes Care. 2015. PMID: 25720600 Free PMC article. Clinical Trial.

140

Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective.

Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. Bollyky JB, et al. Diabetes Metab Res Rev. 2015 Sep;31(6):588-94. doi: 10.1002/dmrr.2643. Epub 2015 Apr 23. Diabetes Metab Res Rev. 2015. PMID: 25689602 Free PMC article.

141

β cell death and dysfunction during type 1 diabetes development in at-risk individuals.

Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP; Type 1 Diabetes TrialNet Study Group. Herold KC, et al. J Clin Invest. 2015 Mar 2;125(3):1163-73. doi: 10.1172/JCI78142. Epub 2015 Feb 2. J Clin Invest. 2015. PMID: 25642774 Free PMC article.

142

Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk.

Miao D, Steck AK, Zhang L, Guyer KM, Jiang L, Armstrong T, Muller SM, Krischer J, Rewers M, Yu L; Type 1 Diabetes TrialNet Study Group. Miao D, et al. Diabetes Technol Ther. 2015 Feb;17(2):119-27. doi: 10.1089/dia.2014.0186. Epub 2015 Jan 6. Diabetes Technol Ther. 2015. PMID: 25562486 Free PMC article.

143

Loss of anergic B cells in prediabetic and new-onset type 1 diabetic patients.

Smith MJ, Packard TA, O'Neill SK, Henry Dunand CJ, Huang M, Fitzgerald-Miller L, Stowell D, Hinman RM, Wilson PC, Gottlieb PA, Cambier JC. Smith MJ, et al. Diabetes. 2015 May;64(5):1703-12. doi: 10.2337/db13-1798. Epub 2014 Dec 18. Diabetes. 2015. PMID: 25524915 Free PMC article.

144

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group. Sosenko JM, et al. Diabetes Care. 2015 Feb;38(2):271-6. doi: 10.2337/dc14-1813. Epub 2014 Dec 17. Diabetes Care. 2015. PMID: 25519451 Free PMC article.

145

Effect of docosahexaenoic acid supplementation on inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes.

Chase HP, Boulware D, Rodriguez H, Donaldson D, Chritton S, Rafkin-Mervis L, Krischer J, Skyler JS, Clare-Salzler M; Type 1 Diabetes TrialNet Nutritional Intervention to Prevent (NIP) Type 1 Diabetes Study Group. Chase HP, et al. Pediatr Diabetes. 2015 Jun;16(4):271-9. doi: 10.1111/pedi.12170. Epub 2014 Jul 12. Pediatr Diabetes. 2015. PMID: 25039804 Free PMC article. Clinical Trial.

146

Analysis of β-cell death in type 1 diabetes by droplet digital PCR.

Usmani-Brown S, Lebastchi J, Steck AK, Beam C, Herold KC, Ledizet M. Usmani-Brown S, et al. Endocrinology. 2014 Sep;155(9):3694-8. doi: 10.1210/en.2014-1150. Epub 2014 Jul 8. Endocrinology. 2014. PMID: 25004096 Free PMC article.

147

Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes.

Arif S, Leete P, Nguyen V, Marks K, Nor NM, Estorninho M, Kronenberg-Versteeg D, Bingley PJ, Todd JA, Guy C, Dunger DB, Powrie J, Willcox A, Foulis AK, Richardson SJ, de Rinaldis E, Morgan NG, Lorenc A, Peakman M. Arif S, et al. Diabetes. 2014 Nov;63(11):3835-45. doi: 10.2337/db14-0365. Epub 2014 Jun 17. Diabetes. 2014. PMID: 24939426 Free PMC article.

148

A rule-based prognostic model for type 1 diabetes by identifying and synthesizing baseline profile patterns.

Lin Y, Qian X, Krischer J, Vehik K, Lee HS, Huang S. Lin Y, et al. PLoS One. 2014 Jun 13;9(6):e91095. doi: 10.1371/journal.pone.0091095. eCollection 2014. PLoS One. 2014. PMID: 24926781 Free PMC article. Clinical Trial.

149

Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline.

Orban T, Beam CA, Xu P, Moore K, Jiang Q, Deng J, Muller S, Gottlieb P, Spain L, Peakman M; Type 1 Diabetes TrialNet Abatacept Study Group. Orban T, et al. Diabetes. 2014 Oct;63(10):3449-57. doi: 10.2337/db14-0047. Epub 2014 May 16. Diabetes. 2014. PMID: 24834977 Free PMC article. Clinical Trial.

150

Distribution of C-peptide and its determinants in North American children at risk for type 1 diabetes.

Xu P, Qian X, Schatz DA, Cuthbertson D, Krischer JP; DPT-1 Study Group. Xu P, et al. Diabetes Care. 2014 Jul;37(7):1959-65. doi: 10.2337/dc13-2603. Epub 2014 Apr 23. Diabetes Care. 2014. PMID: 24760262 Free PMC article. Clinical Trial.

151

Recommendations for the definition of clinical responder in insulin preservation studies.

Beam CA, Gitelman SE, Palmer JP; Type 1 Diabetes TrialNet Study Group. Beam CA, et al. Diabetes. 2014 Sep;63(9):3120-7. doi: 10.2337/db14-0095. Epub 2014 Apr 10. Diabetes. 2014. PMID: 24722251 Free PMC article.

152

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Sosenko JM, et al. Diabetes Care. 2014 Apr;37(4):979-84. doi: 10.2337/dc13-2359. Epub 2014 Feb 18. Diabetes Care. 2014. PMID: 24550217 Free PMC article.

153

Total IgA and IgA reactivity to antigen I/II epitopes in HLA-DRB1*04 positive subjects.

McCarlie VW, Hartsfield JK Jr, Blum JS, González-Cabezas C, Chin JR, Eckert GJ, Morford LA, Pescovitz MD, Rodriguez H, Fontana M, Gregory RL. McCarlie VW, et al. Open J Immunol. 2013 Sep 1;3(3):82-92. doi: 10.4236/oji.2013.33012. Open J Immunol. 2013. PMID: 24386612 Free PMC article.

154

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.

Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Abatacept Study Group. Orban T, et al. Diabetes Care. 2014 Apr;37(4):1069-75. doi: 10.2337/dc13-0604. Epub 2013 Dec 2. Diabetes Care. 2014. PMID: 24296850 Free PMC article. Clinical Trial.

155

B-lymphocyte depletion with rituximab and β-cell function: two-year results.

Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Pescovitz MD, et al. Diabetes Care. 2014 Feb;37(2):453-9. doi: 10.2337/dc13-0626. Epub 2013 Sep 11. Diabetes Care. 2014. PMID: 24026563 Free PMC article. Clinical Trial.

156

Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes.

Weinberg A, Boulware D, Dighero B, Orban T; Type 1 Diabetes TrialNet Abatacept Study Group. Weinberg A, et al. Vaccine. 2013 Oct 1;31(42):4791-4. doi: 10.1016/j.vaccine.2013.07.086. Epub 2013 Aug 17. Vaccine. 2013. PMID: 23962535 Free PMC article. Clinical Trial.

157

First test effect in intravenous glucose tolerance testing.

Ismail HM, White KS, Krischer JP, Chase HP, Cuthbertson D, Palmer JP; DPT-1 Study Group. Ismail HM, et al. Pediatr Diabetes. 2015 Mar;16(2):129-37. doi: 10.1111/pedi.12064. Epub 2013 Aug 15. Pediatr Diabetes. 2015. PMID: 23944770 Free PMC article.

158

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. Sosenko JM, et al. Diabetes. 2013 Dec;62(12):4179-83. doi: 10.2337/db13-0656. Epub 2013 Jul 17. Diabetes. 2013. PMID: 23863814 Free PMC article.

159

The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group. Sosenko JM, et al. Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425. Epub 2013 Jul 1. Diabetes Care. 2013. PMID: 23818528 Free PMC article.

160

Decline in titers of anti-idiotypic antibodies specific to autoantibodies to GAD65 (GAD65Ab) precedes development of GAD65Ab and type 1 diabetes.

Larsson HE, Jönsson I, Lernmark A, Ivarsson S, Radtke JR, Hampe CS; Diabetes Prediction in Skåne (DiPiS); Type 1 Diabetes Trial Network. Larsson HE, et al. PLoS One. 2013 Jun 13;8(6):e65173. doi: 10.1371/journal.pone.0065173. Print 2013. PLoS One. 2013. PMID: 23785410 Free PMC article.

161

Insights into type 1 diabetes from the autoimmune polyendocrine syndromes.

Cheng MH, Anderson MS. Cheng MH, et al. Curr Opin Endocrinol Diabetes Obes. 2013 Aug;20(4):271-8. doi: 10.1097/MED.0b013e32836313eb. Curr Opin Endocrinol Diabetes Obes. 2013. PMID: 23770732 Free PMC article. Review.

162

The use of intermediate endpoints in the design of type 1 diabetes prevention trials.

Krischer JP; Type 1 Diabetes TrialNet Study Group. Krischer JP, et al. Diabetologia. 2013 Sep;56(9):1919-24. doi: 10.1007/s00125-013-2960-7. Epub 2013 Jun 7. Diabetologia. 2013. PMID: 23744306 Free PMC article.

163

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.

Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Canakinumab Study Group; Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T; AIDA Study Group. Moran A, et al. Lancet. 2013 Jun 1;381(9881):1905-15. doi: 10.1016/S0140-6736(13)60023-9. Epub 2013 Apr 5. Lancet. 2013. PMID: 23562090 Free PMC article. Clinical Trial.

164

Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes.

Kroll JL, Beam C, Li S, Viscidi R, Dighero B, Cho A, Boulware D, Pescovitz M, Weinberg A; Type 1 Diabetes TrialNet Anti CD-20 Study Group. Kroll JL, et al. J Clin Virol. 2013 Jun;57(2):115-9. doi: 10.1016/j.jcv.2013.01.016. Epub 2013 Feb 17. J Clin Virol. 2013. PMID: 23422292 Free PMC article. Clinical Trial.

165

Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil.

Loechelt BJ, Boulware D, Green M, Baden LR, Gottlieb P, Krause-Steinrauf H, Weinberg A; Type 1 Diabetes TrialNet Daclizumab/Mycophenolic Acid Study Group. Loechelt BJ, et al. Clin Infect Dis. 2013 Jan;56(2):248-54. doi: 10.1093/cid/cis848. Epub 2012 Oct 5. Clin Infect Dis. 2013. PMID: 23042974 Free PMC article.

166

Performance of HbA1c as an early diagnostic indicator of type 1 diabetes in children and youth.

Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M, Rewers MJ, Schatz DA, Krischer JP; TEDDY, TRIGR, Diabetes Prevention Trial–Type 1, and Type 1 Diabetes TrialNet Natural History Study Groups. Vehik K, et al. Diabetes Care. 2012 Sep;35(9):1821-5. doi: 10.2337/dc12-0111. Epub 2012 Jun 14. Diabetes Care. 2012. PMID: 22699293 Free PMC article.

167

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.

Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM; Type 1 Diabetes TrialNet Study Group. Greenbaum CJ, et al. Diabetes. 2012 Aug;61(8):2066-73. doi: 10.2337/db11-1538. Epub 2012 Jun 11. Diabetes. 2012. PMID: 22688329 Free PMC article.

168

The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1.

Sosenko JM, Skyler JS, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. Sosenko JM, et al. Diabetes. 2012 Jun;61(6):1331-7. doi: 10.2337/db11-1660. Diabetes. 2012. PMID: 22618768 Free PMC article. Review. No abstract available.

169

Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies.

Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL; Type 1 Diabetes TrialNet Study Group. Yu L, et al. Diabetes Care. 2012 Jun;35(6):1213-8. doi: 10.2337/dc11-2081. Epub 2012 Mar 23. Diabetes Care. 2012. PMID: 22446173 Free PMC article.

170

A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T, Eisenbarth G; Diabetes Prevention Trial–Type 1 and Type 1 Diabetes TrialNet Study Groups. Sosenko JM, et al. Diabetes Care. 2011 Nov;34(11):2435-7. doi: 10.2337/dc11-0981. Epub 2011 Sep 12. Diabetes Care. 2011. PMID: 21911777 Free PMC article.

171

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Abatacept Study Group. Orban T, et al. Lancet. 2011 Jul 30;378(9789):412-9. doi: 10.1016/S0140-6736(11)60886-6. Epub 2011 Jun 28. Lancet. 2011. PMID: 21719096 Free PMC article. Clinical Trial.

172

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet GAD Study Group. Wherrett DK, et al. Lancet. 2011 Jul 23;378(9788):319-27. doi: 10.1016/S0140-6736(11)60895-7. Epub 2011 Jun 27. Lancet. 2011. PMID: 21714999 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

172 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Results by year